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Decreased phosphorylation of focal adhesion kinase
and paxillin is associated with loss of focal adhesions
and stress fibers and precedes the onset of apoptosis
(van de Water, B., Nagelkerke, J. F., and Stevens, J. L.
(1999) J. Biol. Chem. 274, 13328–13337). The cortical ac-
tin cytoskeletal network is also lost during apoptosis,
yet little is known about the temporal relationship be-
tween altered phosphorylation of proteins that are crit-
ical in the regulation of this network and their potential
cleavage by caspases during apoptosis. Adducins are
central in the cortical actin network organization. Cis-
platin caused apoptosis of renal proximal tubular epi-
thelial cells, which was associated with the cleavage of
a-adducin into a 74-kDa fragment; this was blocked by a
general caspase inhibitor benzyloxycarbonyl-Val-Ala-
Asp-fluoromethyl ketone (z-VAD-fmk). Hemagglutinin-
tagged human a-adducin was cleaved into a similar 74-
kDa fragment by caspase-3 in vitro but not by caspase-6
or -7. Asp-Arg-Val-Asp29-Glu, Asp-Ile-Val-Asp208-Arg, and
Asp-Asp-Ser-Asp633-Ala were identified as the principal
caspase-3 cleavage sites; Asp-Asp-Ser-Asp633-Ala was key
in the formation of the 74-kDa fragment. Cisplatin also
caused an increased phosphorylation of a-adducin and
g-adducin in the MARCKS domain that preceded a-ad-
ducin cleavage and was associated with loss of adducins
from adherens junctions; this was not affected by z-VAD-
fmk. In conclusion, the data support a model in which
increased phosphorylation of a-adducin due to cisplatin
leads to dissociation from the cytoskeleton, a situation
rendered irreversible by caspase-3-mediated cleavage of
a-adducin at Asp-Asp-Ser-Asp633-Ala.
Apoptosis or programmed cell death is critical for tissue
development and homeostasis (1). Uncontrolled apoptosis,
which may occur after exposure to toxic chemicals, is a patho-
physiological process associated with various human diseases
(2, 3). Commitment to apoptosis requires activation of caspases,
a family of aspartate-directed cysteinyl-containing proteases
(4). The caspase family consists of at least 14 different pro-
teases that can be subdivided based on sequence homology into
caspase-1- and caspase-3-like caspases and functionally into
upstream caspases (caspases-8, -9, and -10) and terminal exe-
cutioner caspases (caspases-3, -6, and -7) (4). The caspase-3
subgroup is considered to be critical in the autolytic phase of
apoptosis (4). Thus, proteolytic activation of pro-caspase-3 by
either of the upstream caspases-8 or -9 results in cleavage of
proteins at DXXD sites by caspase-3 (4–6). A variety of pro-
teins, including poly(ADP-ribose) polymerase, DNA-dependent
protein kinase, Rb, Mdm2, Bcl-2, and protein kinase C d, have
been identified as substrates (4). It has been suggested that the
net gain or loss of function caused by proteolysis of caspase
substrates is required for progression of the apoptotic program.
In this respect, is has been proposed that caspase-3-mediated
cleavage of cytoskeletal (-associated) components, such as
lamin A (7, 8), gelsolin (9, 10), actin (11, 12), focal adhesion
kinase (13–15), GAS-2 (16), and fodrin (17–19) may actually
initiate morphological alterations observed during apoptosis,
i.e. cell shrinkage, loss of cell-matrix and cell-cell interactions
and formation of apoptotic bodies.
Cell-matrix and cell-cell interactions provide survival sig-
nals (20–23), including activation of phosphoinositide-3 ki-
nase and protein kinase B/Akt signaling cascades (24–26).
The actin cytoskeletal network is important in maintaining
these interactions, whereas loss of cell-cell and cell-matrix
interactions signals caspase activation and apoptosis (20–23,
27, 28). In a recent study (15) we showed that during chem-
ically induced apoptosis of rat proximal tubule epithelial
(RPTE)1 cells, loss of actin cytoskeletal organization and
cell-matrix interactions occurs independent of caspase activ-
ity. Disruption of the F-actin cytoskeletal network by xeno-
biotics and loss of both focal adhesion kinase and paxillin
from the focal adhesion occurred before caspase activation and
was not blocked by caspase inhibitors but was associated with
loss of tyrosine phosphorylation of both proteins (15). Caspase
cleavage of focal adhesion kinase occurred later (15). The data
suggested a model in which loss of focal adhesion integrity results
from toxicant-induced changes in signaling. Although caspase
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cleavage did not initiate the disruption by inducing a gain or loss
of function, it did render the process irreversible, ensuring that
the cell is committed to apoptosis.
Preliminary observations also suggested that cell-cell con-
tact was also disrupted during xenobiotic-induced apoptosis.
Cell-cell interactions are mediated through homophilic inter-
actions between E-cadherins at the adherens junctions (29).
E-cadherin is linked through b- and a-catenin to the cortical
F-actin network (29); the latter interacts with the cortical spec-
trin cytoskeletal network (30). This cortical F-actin network is
regulated by various regulatory proteins, such as Tiam-1, c-Src,
and Rho-family members as well as cytoskeletal-associated
proteins, including adducins (29, 31–33). Cell-cell interactions
are disrupted during apoptosis, and some proteins of the adhe-
rens junction are caspase-3 substrates (17–19). However, little
is known about the involvement of caspases in disruption of the
cortical actin cytoskeleton during drug-induced apoptosis.
Therefore, we investigated the fate of the cortical actin-capping
protein adducin in relation to cisplatin-induced apoptosis in
renal epithelial cells.
Adducins are cytoskeletal proteins composed of highly re-
lated a and b or a and g subunits that bind to the fast-
growing ends and the sides of actin filaments (34–38). Ad-
ducins consist of three distinct domains: an N-terminal head,
involved in dimerization, a neck, and C-terminal tail domain
containing the MARCKS-related domain that recruits spec-
trin/fodrin to the fast-growing ends of actin filaments (35–37,
39, 40). Adducin function is modulated by several kinases:
Rho kinase, protein kinase A (PKA), and protein kinase C
(PKC) (33, 41–44). Rho kinase phosphorylates adducin in the
neck domain, resulting in increased association of a-adducin
with F-actin (33, 45). PKA phosphorylates a-adducin at
Ser408, Ser436, and Ser481 in the neck domain, and PKC and
PKA phosphorylate at Ser726 in the MARCKS domain (42).
PKA-mediated phosphorylation of adducin results in reduced
formation of actin-spectrin complexes (42), whereas PKC-
mediated phosphorylation results in an accumulation of
phosphorylated adducin in the cytosol (41, 43). Although
adducin is a cytoskeletal component important for controlling
the cortical cytoskeletal network, to our knowledge there is
little or no data available on its involvement in cytoskeleton
rearrangements before apoptosis or the fate of adducin dur-
ing apoptosis. To investigate this we have used nephrotoxi-
cant-induced apoptosis of renal proximal tubular epithelial
cells as a model.
RPTE cells are a target for many chemicals as well as ische-
mia/reperfusion injury (46, 47), which may cause apoptosis in
vitro and in vivo (15, 48, 49), a process associated with loss of
cell-cell and cell-matrix interactions (15, 50–53). Since we used
the RPTE cell model to investigate the role of caspases in loss
of focal adhesion integrity during apoptosis, we used RPTE
cells to address the relationship between adherens junction
organization, adducin phosphorylation, and proteolysis in
chemically induced apoptosis. Apoptosis of RPTE cells was
preceded by an early increased phosphorylation of primarily
a-adducin at Ser726, most likely by a PKC isoform that corre-
lated with a loss of adducin in adherens junctions. This was
followed by activation of caspases and induction of apoptosis.
a-Adducin (but not g-adducin) was cleaved by a caspase-3-de-
pendent manner at Asp-Arg-Val-Asp29-Glu and Asp-Asp-Ser-
Asp633-Ala to yield a 74-kDa fragment in RPTE cells. The data
indicate that phosphorylation of a-adducin and disruption of




Dulbecco’s modified Eagle’s medium/Ham’s F-12, a-modified mini-
mal essential medium with ribonucleosides and deoxyribonucleosides,
penicillin/streptomycin/amphotericin, and trypsin/EDTA were from
Life Technologies, Inc. Fetal calf serum was from Bodinco (Alkmaar,
The Netherlands). Bovine serum albumin fraction V, cholera toxin,
insulin, AMC, doxorubicin, staurosporin, and cisplatin were from
Sigma. Epidermal growth factor was from Upstate Biotechnology Inc.
(Lake Placid, NY). Benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ke-
tone (z-VAD-fmk), acyl-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO), acyl-
Tyr-Val-Ala-Asp-7-amino-4-methylcoumarin (Ac-YVAD-AMC), acyl-
Val-Glu-Ile-Asp-7-amino-4-methylcoumarin (Ac-VEID-AMC), calpain
inhibitor I and II were from Bachem (Bubendorf, Switzerland). Acyl-
Asp-Glu-Val-Asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) was
from Research Biochemicals International (Natick, MA).
Plasmids
An expression vector for hemagglutinin (HA)-tagged human a-addu-
cin (amino acids 1–737; pEF-BOS-HA-a-adducin) was kindly provided
by Dr. K. Kaibuchi and described elsewhere (33). For site-directed
mutagenesis, the a-adducin-coding region was subcloned into pZErO
(Invitrogen) using KpnI. For mutation by polymerase chain reaction of
amino acid residue D to A at the various caspase-3 cleavage sites in
human a-adducin, the QuickChange mutagenesis kit (Stratagene) was
used with the following primers: Asp29 3 Ala, forward primer 59-
GGTACTTCGACCGAGTAGCTGAGAACAACCC-39 and reverse primer
59-GGGTTGTTCTCCAGCTACTCGGTCGAAGTACC-39; Asp208 3 Ala,
forward primer 59-GGTACTTCGACCGAGTAGCTGAGAACAACCC-39
and reverse primer 59-GGGTTGTTCTCAGCTACTCGGTCGAAGTAC-
C-39; Asp6333 Ala, forward primer 59-GGAGATGACAGTGCTGCTGC-
CACCTTTAAGC-39 and reverse primer 59-GCTTAAAGGTGGCAGCA-
GCACTGTCATCTCC-39. The correct sequences after mutation were
confirmed by DNA cycle sequencing. Mutated a-adducin was subcloned
back into pEF-BOS. Correct expression of HA-a-adducin and the differ-
ent Asp 3 Ala mutants was checked by transient overexpression in
COS1 cells followed Western blotting and immunofluorescent staining.
Cell Culture and Treatment
RPTE cells were isolated by collagenase perfusion and separated by
density centrifugation using Nycodenz as described (54, 55). Cells were
cultured on rat tail collagen (Collaborative Research, Bedford, MA)-
coated dishes in Dulbecco’s modified Eagle’s medium /F-12 containing
1% v/v fetal bovine serum, 0.5 mg/ml bovine serum albumin, 10 mg/ml
insulin, 10 ng/ml epidermal growth factor, 10 ng/ml cholera toxin, and
antibiotics as described (complete medium A; Refs. 15 and 56). Cells
were maintained at 37 °C in a humidified atmosphere of 95% air and 5%
carbon dioxide and fed every other day. RPTE cells were used after they
had reached confluence, 6 to 9 days after plating.
For experiments, confluent monolayers of RPTE cells in 24-well
dishes containing coated glass coverslips, 6-well or 10-cm dishes (Corn-
ing Costar, Acton, MA), were washed with Earle’s balanced salt solution
once. Thereafter, cells were treated with cisplatin in Hanks’ balanced
salt solution (137 mM NaCl, 5 mM KCl, 0.8 mM MgSO4z7 H2O, 0.4 mM
Na2HPO4z2 H2O, 0.4 mM KH2PO4, 1.3 mM CaCl2, 4 mM NaHCO3, 25 mM
HEPES, 5 mM D-glucose, pH 7.4, in a final volume of 1, 2, or 10 ml,
respectively, for 8 h. In some experiments the general caspase inhibitor
z-VAD-fmk (100 mM; 100 mM stock in Me2SO) was added simulta-
neously with cisplatin. Following treatment with cisplatin for 8 h, cells
were allowed to recover in complete medium in the presence or absence
of z-VAD-fmk.
Determination of Cell Death
Cell Cycle Analysis—Apoptosis was determined by cell cycle analysis
as described (15). Briefly, floating as well as adherent cells that were
trypsinized were fixed in 90% ethanol (220 °C). After washing cells
twice with PBS, 1 mM EDTA cells were resuspended in PBS-EDTA
containing 7.5 mM propidium iodide and 10 mg/ml RNase A. After a
30-min incubation at room temperature, the cell cycle was analyzed by
flow cytometry (FACS-Calibur, Becton Dickenson), and the percentage
of cells present in sub-G0/G1 was calculated using the Cellquest soft-
ware (Becton Dickenson).
Lactate Dehydrogenase Release—Cell death was measured by the
release of lactate dehydrogenase from cells in the culture medium as
described (57). The percentage cell death was calculated from the
amount of lactate dehydrogenase release caused by treatment with























toxicants relative to the amount to that released by 0.1 w/v Triton
X-100, i.e. 100% release.
Caspase Activity—Briefly, attached and detached cells were har-
vested and collected by centrifugation as above. The cell pellet was
taken up in lysis buffer (10 mM HEPES, 40 mM b-glycerophosphate,
50 mM NaCl, 2 mM MgCl2, and 5 mM EGTA) and subjected to 3 cycles of
freezing and thawing. Equal amounts of cell proteins were used in a
caspase assay using Ac-DEVD-AMC, Ac-YVAD-AMC, or Ac-VEID-AMC
(25 mM; Research Biochemicals) as a substrate. Fluorescence derived
from release of the AMC moiety was followed using a fluorescence plate
reader (HTS 7000 Bio assay reader; Perkin-Elmer). Caspase activity
was calculated as pmol/mg of cell proteinzmin using AMC as a standard.
In Vitro Caspase-Substrate Cleavage Assay
For transfection, 2 3 105 COS1 cells were plated in 6-well culture
clusters. After overnight culturing, COS1 cells were transfected with
0.4 mg of pEF-BOS-a-adducin, pEF-BOS-a-adducin-Asp29 3 Ala, pEF-
BOS-a-adducin-Asp208 3 Ala, or pEF-BOS-a-adducin-Asp633 3 Ala
using LipofectAMINEPlus (Life Technologies, Inc.) according to the
manufacturer’s procedures. After 24 h, cells were harvested in TSE
buffer plus inhibitors (10 mM Tris/HCl, pH 7.4, 250 mM sucrose, 1 mM
EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10
mg/ml leupeptin, 10 mg/ml aprotinin) followed by sonication (3 3 5 s).
Protein was determined using the Bradford reagent (Bio-Rad). 15 mg of
COS1 cell lysate was dissolved in caspase assay buffer (50 mM HEPES,
2 mM EDTA, 0.1% (w/v) CHAPS, 10% (w/v) sucrose, pH 7.0, containing
10 mM dithiothreitol, 20 mg/ml leupeptin, 20 mg/ml aprotinin, 20 mg/ml
pepstatin, and 20 mM phenylmethylsulfonyl fluoride). After the addi-
tion of 0.1 mg of recombinant human caspase 3, 6, or 7 (gift from D.
Nicholson and N. Thornberry, Merck Frosst, Montreal, Canada), the
reaction mixture was incubated for 1 h at 37 °C. Where indicated, 5 mM
z-VAD-fmk, 5 mM Ac-DEVD-CHO, or 5 mM calpain inhibitor I or 5 mM
calpain inhibitor II was also added. The cleavage reaction was stopped
by the addition of Laemmli sample preparation buffer followed by
heating for 5 min at 95 °C. Samples were separated by SDS-PAGE
followed by Western blotting.
For immunoprecipitation of HA-tagged human a-adducin, 25 mg
protein of total COS1 cell lysate was dissolved in 500 ml of radioimmune
precipitation buffer (50 mM Tris/HCl, 150 mM NaCl, 1 mM EDTA, 1.0%
(w/v) deoxycholate, 1.0% (w/v) Triton X-100, 0.2% (w/v) sodium dodecyl
sulfate, pH 7.4, containing the above protease inhibitors) followed by
pre-clearing by centrifugation (30 min, 13,000 rpm). The supernatant
was incubated with anti-HA antibody (clone 12CA5) for 1 h at 4 °C
followed by incubation with protein G-Sepharose beads (Sigma) for 1 h
at 4 °C. After 3 washes with low salt buffer (50 mM HEPES, 150 mM
NaCl, 1 mM EDTA, 0.1% (v/v) Nonidet P-40, pH 7.4, containing protease
inhibitors), beads were resuspended in caspase assay buffer. Next, 0.1
mg of human recombinant caspase-3 was added, and the mixture was
incubated for 1 h at 37 °C with or without 5 mM Ac-DEVD-CHO. The
cleavage reaction was stopped by the addition of Laemmli sample
preparation buffer followed by heating for 5 min at 95 °C. Samples were
separated by SDS-PAGE followed by Western blotting.
Preparation of Cytoskeletal and Soluble Cellular Fractions
To obtain soluble and cytoskeletal fractions, the Triton X-100 extrac-
tion method was used (41, 58). Briefly, RPTE cells cultured in 10-cm
dishes were treated with cisplatin as above. The medium was removed,
and adherent cells were washed twice with PBS and a final wash with
microtubule stabilization buffer (MSB; 100 mM PIPES, 2 M glycerol, 1
mM EGTA, 1 mM magnesium acetate, pH 6.9). Adherent cells were
scraped in 500 ml of MSB buffer containing protease and phosphatase
inhibitors and 0.2% (w/v) Triton X-100 (MSB Plus). Floating cells were
collected from the pooled washes by centrifugation for 5 min at 500 3 g.
Pelleted cells were mixed with the adherent cells in MSB buffer. Cells
were extracted for 4 min at room temperature. The homogenate was
centrifuged at 85,000 3 g for 20 min at 15 °C. The supernatant (soluble
fraction) was removed, and the pellet (cytoskeleton fraction) was resus-
pended in MSB Plus. Equal amounts of protein were separated by
SDS-PAGE followed by Western blotting.
Gel Electrophoresis and Immunoblotting
Cells were scraped in ice-cold PBS and pooled with medium contain-
ing floating cells. After centrifugation (5 min, 500 3 g, 4 °C), the pellet
was resuspended in TSE plus inhibitors. Protein concentration in the
supernatant was determined using the Bradford protein assay using
IgG as a standard. Equal amounts of total cellular protein were sepa-
rated by SDS-PAGE and transferred to polyvinylidene difluoride mem-
brane (Millipore). Blots were blocked with 5% w/v nonfat dry milk in
TBS-T (0.5 M NaCl, 20 mM Tris-HCl, 0.05% v/v Tween 20, pH 7.4) and
probed with anti-poly(ADP-ribose) polymerase (monoclonal C2.10, En-
zyme System Products, Dublin, CA), anti-a-adducin, and anti-g-addu-
cin (both polyclonal; Refs. 43 and 58), anti-fodrin (polyclonal, kindly
provided by Dr. W. Nelson), anti-HA (clone 3F10, Roche Molecular
Biochemicals), or anti-focal adhesion kinase (Transduction Laborato-
ries) followed by incubation with horseradish peroxidase-coupled sec-
ondary antibodies (Jackson Laboratories). Visualization was done with
the ECL reagent (Amersham Pharmacia Biotech).
Immunofluorescence and Imaging Techniques
For immunofluorescence studies, RPTE cells were cultured on colla-
gen-coated glass coverslips in 24-well dishes. After treatment with
cisplatin, cells were fixed with 3.7% formaldehyde for 10 min followed
FIG. 1. a-Adducin is cleaved during cisplatin-induced apoptosis of RPTE cells. RPTE cells were treated with varying concentrations of
cisplatin for 8 h and allowed to recover for another 16 h in complete culture medium, after which samples were taken for further analysis. Cell
death was analyzed by measuring lactate dehydrogenase release (A) or by quantitation of percentage of cells with sub-G0/G1 DNA content by cell
cycle analysis (B) as described under “Experimental Procedures.” Ac-Asp-Glu-Val-Asp-AMC cleavage activity (DEVDas activity) (C) was deter-
mined in cell extracts using Ac-DEVD-AMC as a substrate and expressed as fold over control; DEVDase activity in untreated RPTE cells was 165 6
71 pmol/min/mg (n 5 4). Cleavage of poly(ADP-ribose) polymerase (PARP), a-adducin, and g-adducin at 24 h (D) as well as the time course of
a-adducin cleavage (E) in total cell homogenates was determined by Western blotting as described under “Experimental Procedures.” Data shown
are the mean 6 S.E. of (A–C) or representative for (D and E) four independent experiments (n 5 4). IB, immunoblots.























by 3 washes with PBS. After cell lysis and blocking with PBS, 0.2% w/v
Triton X-100, 0.5% w/v bovine serum albumin, pH 7.4 (PTB), cells were
stained for a-adducin (5 mg/ml), g-adducin (5 mg/ml), or fodrin (10
mg/ml) diluted in PTB. During the staining period of the cells with
secondary Alexa488-labeled goat anti-rabbit antibody (Molecular
Probes, Eugene, OR), the F-actin cytoskeletal network was labeled with
rhodamine-phalloidin at 0.3 units/ml (Molecular Probes). Cells were
mounted on glass slides using Aqua-Poly/Mount (Polysciences Inc.,
Warrington, PA). Cells were viewed using a Bio-Rad 600 MRC confocal
laser scanning microscope.
RESULTS
a-Adducin Is Cleaved during Apoptosis—Exposure to the
nephrotoxicant cisplatin for 8 h followed by recovery in com-
plete medium resulted in a time- and concentration-dependent
cell death in RPTE cells (Fig. 1A). Cell death was associated
with markers of apoptosis, including an increase in the per-
centage of cells with hypodiploid (sub-G1/G0) DNA content and
an increase in caspase-3-like activity (Fig. 1, B and C). In
addition, poly(ADP-ribose) polymerase, a prototypical caspase
substrate, was cleaved to the signature 85-kDa fragment (Fig.
1D). In a similar fashion a-adducin was cleaved into a ;74-kDa
fragment in both a time- and concentration-dependent manner
(Fig. 1, D and E). Although a-adducin was cleaved during
cisplatin-induced apoptosis, g-adducin, the other major addu-
cin in epithelial cells, was not (Fig. 1D).
a-Adducin Cleavage Is Dependent on Caspase Activity—The
fact that adducin cleavage coincided with an increase in
caspase activity and cleavage of other known caspase sub-
strates (i.e. the cytoskeletal protein fodrin and poly(ADP-ri-
bose) polymerase) suggested that a-adducin is a novel caspase
substrate. To test whether a-adducin cleavage was dependent
on caspase activity, RPTE cells were treated with cisplatin
with or without the general caspase inhibitor z-VAD-fmk. As
expected, apoptosis as well as poly(ADP-ribose) polymerase
and focal adhesion kinase cleavage was blocked by z-VAD-fmk
(Fig. 2). z-VAD-fmk also prevented the loss of intact a-adducin
and accumulation of the 74-kDa fragment (Fig. 2). Fodrin in-
teracts with a-adducin and is cleaved by caspases and calpain
in other cell types (18, 19, 37, 39). In RPTE cells, cisplatin
caused cleavage of fodrin into 145-kDa and 120-kDa fragments
(Fig. 2). Formation of the 120-kDa fragment was blocked by
z-VAD-fmk, but the 145-kDa fragment was still formed. For-
mation of the latter is dependent on calpains (19).
a-Adducin Is Cleaved by Caspase-3 but Not -6 and -7—The
caspase family consists of “upstream caspases” such as
caspase-8 and -9, which activate the “downstream” executioner
caspases including caspase-3, -6, and -7 (4). To investigate
which of the executioner caspases are capable of cleaving a-ad-
ducin, we prepared extracts of COS1 cells expressing a human
HA-tagged a-adducin. Recombinant caspase-3, but not
caspase-6 and -7, cleaved human a-adducin in cell extracts into
a fragment of approximately 74 kDa (Fig. 3), the same molec-
ular mass fragment found in apoptotic cells (see Figs. 1 and 2).
In the in vitro cleavage reaction, a fragment of around 78 kDa
was also present (Fig. 3A). Caspase-3, but not caspase-6 and -7,
cleaved endogenous fodrin into a fragment with a molecular
mass of 120 kDa, identical to that observed in RPTE cells (Fig.
3). Despite the inability of recombinant caspase-6 and -7 to
cleave a-adducin, these caspases cleaved fluorescent-labeled
peptide substrates in in vitro protease assays (data not shown).
Altogether, the data indicate that a-adducin is a substrate for
caspase-3, and not caspase-6 or -7.
Calpains are calcium-dependent proteases that are also ac-
tivated during apoptosis and cleave cytosketetal proteins, in-
cluding fodrin (Ref. 19; see above). It seemed possible that
cleavage of a-adducin by caspase-3 in vitro might involve a
pathway whereby caspase-3 would activate calpains and indi-
rectly mediate cleavage of a-adducin. To exclude this possibil-
ity we treated cell extracts with caspase-3 either in the absence
or presence of calpain inhibitors or caspase-3 inhibitors. Cleav-
age of a-adducin by caspase-3 was inhibited by both z-VAD-fmk
and Ac-DEVD-CHO; however, calpain inhibitor I did not block
the caspase-3-mediated processing of a-adducin (Fig. 3). In
intact RPTE cells, both calpain inhibitor I as well as calpain
inhibitor II were unable to prevent formation of the 74-kDa
a-adducin fragment after exposure to cisplatin. In fact, calpain
inhibitors themselves caused apoptosis of RPTE cells, which
was associated with activation of caspases and cleavage of
a-adducin (data not shown). Thus, caspase-3-mediated cleav-
age is independent of calpain activity and is, most likely, di-
rectly mediated by caspase-3.
Since the data suggested that caspase-3 is responsible for
cleavage of a-adducin, we focused on potential caspase-3 cleav-
age sites in a-adducin. Incubation of HA-tagged a-adducin with
caspase-3 resulted in the formation of two major cleavage prod-
ucts of around 74 and 78 kDa (see above). However, with
prolonged exposure, several minor fragments of approximately
of 26, 50, and 60 kDa were also observed on autoradiograms
(Fig. 4A). Since the HA-tag contains a caspase-3 cleavage site,
staining for HA was not possible, making identification of N-
terminal cleavage fragments difficult. To circumvent this, we
treated HA-a-adducin with caspase-3 after immunoprecipita-
tion with anti-HA antibody to shield the HA tag. After immu-
noprecipitation, HA-a-adducin was cleaved by caspase-3 into 2
HA-containing fragments of 28 kDa and 78 kDa (Fig. 4B).
Formation of all the above fragments was blocked by incuba-
tion with Ac-DEVD-CHO (Fig. 4, A and B). Thus, caspase-3
cleaves a-adducin in to 2 major (74 and 78 kDa) and 4 minor
fragments (26, 28, 50, and 60 kDa).
The consensus caspase-3 cleavage site is DEVD. The two
aspartic acid residues are absolutely required, but the glutamic
acid and valine residues may vary; therefore, any DXXD is a
potential site (4). Comparison of rat and human a-adducin
revealed three conserved DXXD sequences; two in the N-ter-
minal region at Asp-Arg-Val-Asp29-Glu and Asp-Ile-Val-
Asp208-Arg and one in the C terminus at Asp-Xaa-Ser-Asp633-
Ala (Fig. 5). These cleavage sites are unique for a-adducin and
FIG. 2. The caspase inhibitor z-VAD-fmk blocks a-adducin
cleavage during apoptosis. RPTE cells were treated with or without
cisplatin (100 mM) in the absence or presence of z-VAD-fmk (100 mM) for
8 h and allowed to recover for another 16 h in complete culture medium
with or without z-VAD-fmk (100 mM). Thereafter samples were taken
for further analysis by Western blotting for a-adducin, fodrin, poly-
(ADP-ribose) polymerase (PARP), and focal adhesion kinase (FAK)
cleavage as described under “Experimental Procedures.” Apoptosis was
determined by quantitation of the percentage of cells with sub-G0/G1
DNA content by cell cycle analysis. Data shown are representative for
four independent experiments (n 5 4).























are not present in either b- or g-adducin (Fig. 5). Cleavage of
a-adducin at the N-terminal Asp-Arg-Val-Asp29 or Asp-Ile-Val-
Asp208 and the C-terminal Asp-Xaa-Ser-Asp633 sites would re-
sult in 9 different fragments with the expected masses shown
in Fig. 4C. The 74-kDa major product found in apoptotic cells is
consistent with a fragment containing amino acids 30–633.
The 4-kDa fragment is not detectable due to its small size but
would account for a 78-kDa fragment that contains the 74-kDa
product. Of the possible smaller fragments, the predicted 24-
kDa fragment cannot be detected because it lacks an epitope
recognizable by the a-adducin antibodies used herein. The 12-
kDa fragment was not visible and may not be resolved from the
26-kDa fragment due to altered electrophoretic mobility and/or
an inability to separate these fragments on the gel system
used. Regardless, the sequence data indicate that Asp-Arg-Val-
Asp29 and Asp-Xaa-Ser-Asp633 are likely cleavage sites for the
generation of the major 74-kDa fragment seen in apoptotic
cells.
Asp-Asp-Ser-Asp633-Ala Is the Key Caspase-3 Cleavage Site
in a-Adducin—To investigate the role of these DXXD sites in
FIG. 4. Caspase-3 cleavage products of HA-tagged human a-
adducin. COS-1 cells were transfected with 0.4 mg of pEF-BOS-HA-
alpha-adducin. A, 15 mg of total cell homogenate was incubated with
caspase-3 (100 ng), and a-adducin fragments were detected by Western
blotting using the clone45 anti-a-adducin polyclonal antibody. B, 25 mg
of total cell homogenate was immunoprecipitated (IP) with anti-HA
antibody (clone 12CA5) followed by incubation with caspase-3 (100 ng)
either in the absence or presence of Ac-DEVD-CHO (5 mM). HA tag-
containing fragments were detected by Western blotting using rat an-
ti-HA antibody (clone 3F10). IB, immunoblots. C, potential HA-a-addu-
cin cleavage fragments and recognition by either anti-HA or anti-a-
adducin antibody.
FIG. 5. Potential caspase-3 cleavage sites in a-adducin and
sequence homology with b- and g-adducin. Cleavage sites in hu-
man (GenBanky accession number X58141) and rat (GenBanky acces-
sion number Z49081) a-adducin. Sequence homology for the two cleav-
age sites in highly homologous N-terminal head region in human
b-adducin (GenBanky accession number X58199) and rat (GenBanky
accession number U35775) and human (GenBanky accession number
U37122) g-adducin as well as potential caspase cleavage sites in the
variable tail region are indicated.
FIG. 3. Caspase-3 but not -6 and -7
cleaves HA-tagged a-adducin. COS-1
cells were transfected with 0.4 mg of pEF-
BOS-HA-a-adducin. A, 15 mg of total cell
lysate was incubated with 100 ng of hu-
man recombinant (rh) caspase-3, -6, or -7
as described under “Experimental Proce-
dures,” and cleavage of a-adducin, g-ad-
ducin, and fodrin was analyzed by West-
ern blotting. B, 15 mg of total cell
homogenate of COS-1 cells expressing
HA-a-adducin was incubated with 100 ng
of human recombinant caspase-3 in the
presence or absence or calpain inhibitor I
(5 mM), Ac-DEVD-CHO (5 mM), or z-VAD-
fmk (5 mM), and cleavage of a-adducin was
determined by Western blotting using the
anti-a-adducin antibody.























the formation of the various a-adducin fragments, aspartic acid
residue 29, 208, or 633 of human a-adducin were mutated to
alanine by site-directed mutagenesis, resulting in HA-a-ad-
ducin(Asp29 3 Ala), HA-a-adducin(Asp208 3 Ala), and HA-a-
adducin(Asp633 3 Ala). Total cell homogenates of COS-1 cells
transiently transfected with either wild-type or any of the
mutated a-adducin were incubated with caspase-3. Caspase-3
cleaved wild-type a-adducin into the 74- and 78-kDa frag-
ments; cleavage was blocked by Ac-DEVD-CHO (Fig. 6A).
When the concentration of caspase-3 in the incubation was
doubled, almost all a-adducin was degraded, including the
74-kDa fragment (Fig. 6A). Although mutation of Asp29 3 Ala
did not block cleavage of a-adducin, the relative amount of
a-adducin degraded by caspase-3 was reduced compared with
wild-type a-adducin. Furthermore, only one cleavage fragment
of approximately 74–78 kDa was observed (Fig. 6A). The
Asp2083 Ala mutation did not prevent proteolysis of a-adducin
by caspase-3 appreciably (Fig. 6A). Mutation of Asp633 3 Ala
blocked the formation of the 74-kDa cleavage product and
prevented overall loss of a-adducin even at high concentrations
of caspase-3 (Fig. 6A).
Next we investigated which cleavage site is involved in for-
mation of the HA-containing fragments of approximately 28
and 78 kDa. HA-a-adducin was immunoprecipitated followed
by incubation with caspase-3 (Fig. 6B). The Asp29 3 Ala mu-
tation did not block the formation of the 28 and 78 kDa frag-
ments. In contrast, the Asp208 3 Ala mutation blocked forma-
tion of the 28-kDa fragment, whereas the Asp633 3 Ala
mutation blocked formation of the 78-kDa HA-containing frag-
ment as well as the reduction of the overall loss of HA-a-
adducin (Fig. 6B).
In conclusion, the caspase-3 cleavage sites Asp-Arg-Val-
Asp29-Glu and Asp-Xaa-Ser-Asp633-Ala are both involved in
caspase-3-mediated processing of a-adducin to the major 74-
kDa cleavage product found in apoptotic cells. The Asp-Ile-Val-
Asp208-Arg site may be involved in formation of a 28-kDa
N-terminal fragment in vitro cleavage assays, but this species
or the corresponding C-terminal fragments of either 50 or 62
kDa are not seen in apoptotic cells.
The 74-kDa a-Adducin Fragment Associates with the Cy-
toskeletal Fraction in RPTE Cells—The 74-kDa a-adducin frag-
ment lacks the most C-terminal tail region of a-adducin that
contains the MARCKS domain, the critical domain for binding
of adducin to actin filaments (40). To determine if a-adducin
proteolysis altered its association with the cytoskeletal F-actin
network, we probed the soluble (Fig. 7, SOL) and cytoskeletal
fractions (CSK) from RPTE cells for adducin, the 74 kDa frag-
ment, and fodrin. The 74-kDa fragment, but not intact a-addu-
cin, was found in the CSK fraction after apoptosis (Fig. 7). The
loss of intact a-adducin from the CSK fraction was prevented
by z-VAD-fmk. Although g-adducin is not cleaved by caspases,
it also dissociated from the CSK after treatment with cisplatin,
which was not prevented by z-VAD-fmk. Loss of fodrin from the
CSK after cisplatin treatment was also independent of caspase
activity. The 120-kDa caspase-3 fragment of fodrin was present
in the soluble fraction.
Loss of a-Adducin from Adherens Junctions Precedes Its
Caspase-mediated Fragmentation—Loss of cell-cell contacts is
an important phenomenon that occurs in the process of apo-
ptosis. Since adducin family members are important regulators
of the cortical F-actin cytoskeletal network, it seemed possible
that loss of cell-cell contacts was related to a-adducin cleavage.
To test this hypothesis we evaluated the changes in the local-
ization of a-adducin, g-adducin, as well as fodrin with the
adherens junctions in RPTE cells after exposure to cisplatin.
Although a-adducin cleavage was observed only after 24 h
treatment (Fig. 1), altered localization of both a- and g-adducin
as well as fodrin was already disturbed 8 h after treatment
with cisplatin and preceded general loss of the F-actin network
(Fig. 8). This indicates that the loss of the adducin isoforms and
fodrin from adherens junctions is not caused by a-adducin
cleavage. Accordingly, z-VAD-fmk blocked cisplatin-induced
a-adducin cleavage at 24 h (see above) but did not affect cis-
platin-induced early disturbance of adherens junctions (data
not shown).
Loss of a-Adducin from Adherens Junctions Is Associated
with Increased Phosphorylation of Ser726—Phosphorylation of
a- and g-adducin at Ser726 and Ser660 precedes loss of both a-
and g-adducin from adherens junctions after treatment of
RPTE cells with the phorbol ester phorbol 12,13-dibutyrate (41,
58). To determine whether the cisplatin-induced loss of adducin
isoforms from adherens junctions might be due to increased
phosphorylation of a- and/or g-adducin, we analyzed the phos-
phorylation of both a- and g-adducin using a phospho state-
specific antibody directed against the PKC/PKA phosphoryla-
tion site in the MARCKS domain of adducin (43, 58). Cisplatin
FIG. 6. Effect of mutation Asp-Arg-
Val-Asp293 Ala, Asp-Ile-Val-Asp2083
Ala and DDSD633 3 Ala on caspase-3-
mediated cleavage of human HA-a-
adducin. COS-1 cells were transfected
with either wild-type (wt), Asp-Arg-Val-
Asp293 Ala, Asp-Ile-Val-Asp2083 Ala, or
Asp-Asp-Ser-Asp6333 Ala HA-a-adducin.
A, cell homogenates were incubated with
0, 100, or 200 ng of recombinant human
caspase-3 as described in Fig. 5 in the
absence or presence of Ac-DEVD-CHO (5
mM). B, HA-a-adducin was immunopre-
cipitated followed by incubation with 100
ng of human recombinant caspase-3 as
described in Fig. 5. After separation by
SDS-PAGE and transfer to polyvinyli-
dene difluoride membranes, blots were ei-
ther probed with anti-a-adducin (A) or an-
ti-HA antibodies (B) followed by ECL
detection. Data are representative for
three independent experiments.























treatment for 4 or 8 h caused an increase in the phosphoryla-
tion of both a- and g-adducin (Fig. 9A); a-adducin phosphoryl-
ation was most prominent. The increased phosphorylation was
independent of caspase activity, since it was not blocked by
z-VAD-fmk (Fig. 9B). Finally, we determined whether adducin
remained phosphorylated at 24 h. Although most of a-adducin
had disappeared after treatment with cisplatin, the remaining
a-adducin had a similar extent of phosphorylation compared
with control cells (Fig. 10). No phosphorylation was detectable
on the 74-kDa caspase-3-mediated fragment of a-adducin as
expected since the MARKS domain is absent (Fig. 10). Al-
though z-VAD-fmk blocked the cleavage of a-adducin at 24 h, it
did not affect the phosphorylation of a-adducin (Fig. 10).
DISCUSSION
In the present study we have investigated the temporal
relationship between loss of adherens junctions, altered Ser726
phosphorylation and proteolysis of a-adducin, and the induc-
tion of chemically induced apoptosis in RPTE cells. Several
conclusions can be drawn from these investigations. First, cis-
platin-mediated disruption of adherens junctions is associated
with increased phosphorylation of a- and g-adducin. This phos-
phorylation precedes the complete loss of cell-cell interactions
as well as the activation of the apoptotic machinery, i.e. acti-
vation of caspases, and is independent on the activity of
caspases. Second, we present evidence that a-adducin is a
caspase substrate in chemically induced apoptosis of RPTE
cells, whereas g-adducin is not. Cleavage of a-adducin is medi-
ated by the downstream caspase-3, but not -6 or -7. Third, we
have identified Asp-Asp-Ser-Asp633-Ala as the key caspase-3
cleavage site that is required for the formation of the major
74-kDa cleavage fragment seen in cells undergoing apoptosis.
To our knowledge, chemically induced phosphorylation of ad-
ducins as well as caspase-3-mediated proteolysis of a-adducin
has not been reported before. Since loss of cellular interactions
in (chemically induced) apoptosis is common in renal disorders
in humans and animals, our findings may have important
consequences for the understanding of the molecular mecha-
nisms of renal cell injury.
The major caspase-mediated cleavage product of a-adducin
in cells had a mass of 74 kDa. Not only is the predicted mass of
the polypeptide composed of residues 30–633 consistent with a
74-kDa polypeptide, the experimental evidence also suggested
that this fragment arose from caspase-3 cleavage at both Asp-
Arg-Val-Asp29-Glu and Asp-Asp-Ser-Asp633-Ala. Mutation of
Asp29 did not prevent cleavage, but the resulting fragment
coincided with the 78-kDa fragment. Mutation of Asp633 pre-
vented formation of either the 74- or 78-kDa fragments. The
Asp208 mutation did not prevent cleavage appreciably. Thus,
the data support the notion that the 74-kDa fragment seen in
apoptotic cells is derived from cleavage at Asp-Arg-Val-Asp29-
Glu and Asp-Asp-Ser-Asp633-Ala to yield amino acids 30–633.
Moreover, the 74-kDa fragment lacks the MARCKS domain
and was not recognized by the phospho-selective antibody that
recognizes the phosphorylated Ser726 in a-adducin. Taken to-
gether, the data are consistent with cleavage by caspase-3 to
yield a 74-kDa fragment containing amino acid residues 30–
633 of a-adducin.
Cleavage of a-adducin into a 74-kDa fragment was not re-
stricted to cisplatin-induced apoptosis of RPTE cells. A frag-
ment with the same size was also observed in RPTE cells that
were treated with staurosporin or dichlorovinylcysteine as well
as in SV40-transformed human renal proximal tubular epithe-
lial cells treated with cisplatin.2 Moreover, a-adducin proteol-
2 B. van de Water, A. Verbrugge, and G. J. Mulder, unpublished
observations.
FIG. 8. Effect of cisplatin on localization of a-adducin, g-addu-
cin, and fodrin, and F-actin organization. RPTE cells cultured on
collagen-coated glass coverslips were treated with or without cisplatin
(100 mM). After 8 h cells were fixed and stained for F-actin using rhoda-
mine-phalloidin and immunostained for either a-adducin (A), g-adducin
(B), or fodrin (C). Pictures are representative of four independent
experiments.
FIG. 7. Effect of cisplatin on cytoskeletal association of a-ad-
ducin. RPTE cells were treated with cisplatin for 8 h followed by
recovery in complete medium got 24 h, either in the absence or presence
of z-VAD-fmk (100 mM). CSK and soluble (SOL) fractions were prepared
as described under “Experimental Procedures.” Equal amounts of pro-
tein were separated by SDS-PAGE followed by Western blotting for
a-adducin, g-adducin, phospho-adducin, or fodrin. Results shown are
representative for three independent experiments.























ysis into a 74-kDa fragment was also observed in the apoptosis
of rat mammary adenocarcinoma cell line MTLn3 caused by
anticancer drugs,2 indicating that proteolysis of a-adducin is
not restricted to renal epithelial cells and may well be a general
phenomena in apoptosis of various cell types.
The caspase-3-mediated cleavage of a-adducin was not in-
volved in the loss of a-adducin from adherens junctions. Local-
ization of a-adducin was already disturbed before the 74-kDa
a-adducin fragment was detected (Fig. 8); moreover, the gen-
eral caspase inhibitor z-VAD-fmk did not affect the transloca-
tion of a-adducin. The a-adducin redistribution correlated
better with increased phosphorylation at the PKA/PKC phos-
phorylation site in the MARCKS domain of both a- and g-ad-
ducin; this was already evident 4 h after treatment with cis-
platin. Indeed, treatment of RPTE cells with the PKC activator
phorbol 12,13-dibutyrate (300 nM), but not with the cell-perme-
able PKA activator dibutyryl-cAMP (up to 1 mM), results in a
phosphorylation of a- and g-adducin and a translocation of
adducin to the cytosolic fraction, whereas there is no associa-
tion with the cytoskeleton (58).2 The broad spectrum PKC/PKA
inhibitor staurosporin (50 nM) was able to inhibit the cisplatin-
induced phosphorylation of both a- and g-adducin,2 but stau-
rosporin was toxic to RPTE cells, making it difficult to evaluate
the potential role of Ser726 phosphorylation in cytotoxicity.
Although, the exact mechanism of the increased adducin phos-
phorylation remains unclear, preliminary data indicate that
both PKA and PKC inhibitors, e.g. H89, bisindolylmaleimide,
Gö 6983, and Gö 6976, inhibit the cisplatin-induced cell killing
of RPTE cells.2 If this observation is borne out by additional
studies, it would suggest that phosphorylation of Ser726 is also
important in cell killing by cisplatin. Moreover, the data are
consistent with the model proposed previously for dissolution of
focal adhesions, i.e. disturbances in phosphorylation precede
loss of focal adhesions and cleavage of focal adhesion proteins
by caspases.
Although cisplatin caused an increase in the phosphorylation
of a-adducin, an increased phosphorylation of cytoskeletal pro-
teins is not a general phenomenon in cisplatin-induced cytotox-
icity. Thus, tyrosine phosphorylation of focal adhesion kinase is
decreased (15). In addition, focal adhesion kinase dephospho-
rylation occurs before the onset of apoptosis (15). These obser-
vations indicate that changes in the phosphorylation status of
cytoskeletal proteins are a common feature in chemically in-
duced cytotoxicity associated with loss of cell-cell and cell-
matrix interactions. The data fit with a model in which the net
gain and loss of cytoskeletal protein phosphorylation after re-
nal cell damage determines the fate of the cytoskeletal net-
work. As a consequence of cytoskeleton disruption, cell-cell and
cell-matrix interactions may be lost, and if these disturbances
are severe enough, induction of apoptosis may follow.
In summary, the present findings demonstrate that phos-
phorylation of a-adducin at Ser726 is associated with its loss
from adherens junctions; this precedes caspase-3 activation
and cleavage of a-adducin primarily at Asp-Xaa-Ser-Asp633-
Ala. Since cell-cell interactions are important for modulation
of epithelial cell survival and proliferation and some adher-
ens junction proteins, e.g. b-catenin, can function as tran-
scription factors to promote expression of potentially pro-
apoptotic proteins (49, 59, 60), further investigation on the
molecular mechanisms of adherens junction disorganization
and the biological consequences in relation to (chemically
induced) apoptosis is required. However, a common model for
caspase-mediated destruction of focal adhesions and adher-
ens junctions following chemical treatment emerges. Chemi-
cal stress causes changes in phosphorylation that result in
loss of adherens junctions and focal adhesions contacts with
the actin cytoskeleton. Cleavage of key regulatory proteins
such as adducin and focal adhesion kinase results in irrevers-
ible loss of these structures, ensuring release of the damaged
cell from its neighbors and the substratum, a circumstance
likely to result in anoikis.
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